Daiichi Sankyo Company, Limited (FRA:D4S)

Market Cap	29.54B -42.0%
Revenue (ttm)	11.15B +14.3%
Net Income	1.65B +23.9%
EPS	0.89 +27.1%
Shares Out	n/a
PE Ratio	17.86
Forward PE	n/a
Dividend	0.41 (2.55%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	482
Open	16.20
Previous Close	16.00
Day's Range	16.19 - 16.20
52-Week Range	15.27 - 23.91
Beta	n/a
RSI	44.79
Earnings Date	Jan 30, 2026

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ...

• Industry: Pharmaceutical Preparations
• Founded: 1899
• Employees: 19,765
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: D4S

Financial Performance

In fiscal year 2025, Daiichi Sankyo Company's revenue was 1.89 trillion, an increase of 17.77% compared to the previous year's 1.60 trillion. Earnings were 295.76 billion, an increase of 47.34%.

Financial numbers in JPY